Eli Lilly and Company $LLY Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 19.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 165,491 shares of the company’s stock after selling 39,261 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Eli Lilly and Company were worth $129,005,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in LLY. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $27,000. Blume Capital Management Inc. grew its stake in shares of Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares in the last quarter. IMG Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company in the second quarter valued at $35,000. Financial Gravity Asset Management Inc. acquired a new position in shares of Eli Lilly and Company in the first quarter worth about $40,000. Finally, TD Capital Management LLC boosted its stake in Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after acquiring an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $923.35 on Friday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The business has a 50-day moving average of $799.97 and a 200-day moving average of $775.76. The stock has a market capitalization of $872.92 billion, a price-to-earnings ratio of 60.35, a PEG ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $955.46.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same period in the prior year, the firm posted $1.18 earnings per share. The business’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Insider Activity

In other Eli Lilly and Company news, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gabrielle Sulzberger purchased 117 shares of the stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 4,314 shares of company stock worth $2,766,929. 0.14% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of research reports. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday. Morgan Stanley decreased their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research report on Friday, October 3rd. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. JPMorgan Chase & Co. lowered their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 16th. Finally, Berenberg Bank reiterated a “hold” rating and issued a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $960.88.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.